Korro Bio, Inc. Contract Liability (Deferred Revenue)
Korro Bio, Inc. (KRRO) had Contract Liability (Deferred Revenue) of $9.42 million as of 2021-03-31, per its 10-Q filed 2021-05-13.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2022-03-15
- 2021-03-31: Contract with Customer, Liability, Current $9.42M.
- 2020-12-31: Contract with Customer, Liability, Current $14.07M.
- 2020-09-30: Contract with Customer, Liability, Current $24.02M.
- 2020-06-30: Contract with Customer, Liability, Current $35.27M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2021-03-31 | $9.42M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $14.07M 10-K · filed 2022-03-15 |
| 2020-09-30 | $24.02M 10-Q · filed 2020-11-16 |
| 2020-06-30 | $35.27M 10-Q · filed 2020-08-12 |
| 2020-03-31 | $38.67M 10-Q · filed 2020-05-14 |
| 2019-12-31 | $48.15M 10-K · filed 2021-03-29 |
| 2019-09-30 | $49.36M 10-Q · filed 2019-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |